BioPhorum

Viewing related articles

BioPhorum embarks on collaboration platform refresh

Over the last year, BioPhorum has worked to replace a range of IT platforms to make it easier for our members to collaborate. In the past few months, we have replaced a number of systems and introduced Microsoft Dynamics.  The team is now turning attention to the replacement of iMeet Central (IMC) with a SharePoint-powered collaboration platform named the BioPhorum Hub. We will reach out to members for feedback and aim to have...

read more

BioPhorum celebrates its 200th membership

Founded in 2008 with one Phorum, Drug Substance, the BioPhorum collaboration has focused on bringing leaders and SMEs together, mobilizing communities, creating partnerships and replacing isolation with collaboration. Now, BioPhorum is proud to announce Takeda as the 200th membership across its seven Phorums that represent the thriving communities of over 3,400 active participants. In joining BioPhorum Cell & Gene Therapy, Takeda...

read more

Virtual face-to-face meetings extended as CGT celebrates its first successful virtual event

Inaugural virtual face-to-face meeting a success We can confirm that the BioPhorum virtual collaboration model is delivering.  On Friday 6 March we decided to relocate CGT05 from Philadelphia to the cloud, and, from Tuesday 10, our team delivered a three-day meeting virtually.  As well as sharing case studies, delegates engaged in debates, periodically sharing webcams for a more personal experience. The attendance, representing 26 companies,...

read more

Covid-19 – Face-to-face meetings being converted to virtual events

As Covid-19 spreads to new countries and its impact on economic activity starts to mount we want to confirm that BioPhorum’s collaboration model will remain largely unaffected. With teams meeting virtually every two to four weeks, supported by home-based facilitators, we expect progress against our 80+ missions to continue as normal in the coming weeks and months.

read more

Russian release – how to manage the risks of new analytical testing in Russia

The Russian Federal Service for Surveillance in Healthcare currently mandates in-country testing for all batches of biologicals imported into its market. However, later this year, a new regulation will change the testing regimen. This will move from testing all batches (although only tests that are deemed ‘simple’) to testing the first batches of biological products that are imported and then on an annual basis – but performing all tests in the...

read more

As Ask BPOG morphs into Ask BioPhorum, are you asking enough questions of the community?

Since 2013, Ask BPOG has become a great asset for the industry, with more than 3,000 questions being posted and 11,000 responses given. BioPhorum’s member-only Q&A facility has helped companies benchmark their practices and has even helped them avoid some unwise decisions around investments.

read more

BioPhorum announces new CEO

BioPhorum announced today that Dan Spacie has joined the company as Chief Executive Officer. Since December 2019, Dan has been immersing himself in the business, reviewing BioPhorum’s strategy, internal organization and plans.  This has given Dan the time to design and create the CEO role, bridging between our past successes and the needs of the business going forward.

read more

BioPhorum brings together industry leaders

Held in Lausanne, Switzerland, in May, the annual BioPhorum meeting (BioPhorum 2019) attracted some 55 leaders from across the biopharmaceutical industry. With this year’s major theme being the digitalization of biomanufacturing, member companies Boehringer Ingelheim, GSK and Lonza each presented case studies, covering topics such as artificial intelligence in process development, virtual and augmented reality, 3D printing, smart glasses,...

read more

BioPhorum work with Anvisa to reduce approval times by up to one year

BioPhorum is working together with Brazil’s Anvisa to help increase the rate at which approvals are made by up a year. The current approval timeline in Brazil is between 18 months and two years, it is the intention of the Post-Approval Strategies (PAS) workstream to reduce this and support Anvisa to harmonize their approvals with the International Congress for Harmonization (ICH) of which Anvisa are now members. The PAS team has a strategy of...

read more